Urine Omics Predicting IO Therapy Responses in mRCC Patients

Summary

The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic renal cell carcinoma.

Eligibility

Inclusion Criteria:

1. Age \> 20 years
2. Subjects diagnosed as advanced or metastatic renal cell carcinoma (a/mRCC)
3. Subjects who are about to receive IO-based therapy
4. ECOG performance 0, 1, 2, and 3
5. Life expectancy \>3 months
6. eGFR \> 15 ml/min/1.73 m2 (Stage IV Chronic Kidney Disease or better)
7. Willing to sign the informed consent form

Exclusion Criteria:

1. Subjects NOT willing to sign the informed consent form
2. Subjects with active infection or active urinary tract infection, as shown by urinary WBC \> 5/HPF
3. Subjects having co-existing other malignancies that need active treatment. Those subjects with other malignancies that do not need active treatment are allowed to join the study.
4. Subjects taking any immune-modulating agents, including but not limited to corticosteroid, immune-suppressants, etc. at the discretion of recruiting investigators
5. Subjects who have taken any IO-based therapy before.
6. Subjects who have received other systemic anti-cancer therapies within 4 weeks of screening are not allowed. However, subjects who had a washout period of the above agents for \>4 weeks are allowed to enroll. Subjects who have received or are receiving targeted therapy are allowed to join the study.

Conditions2

Browse More Trials